Did you experience any side effects after consuming the medication?
advertisement

Here is the some steps to help you to save money on Vorizol purchase.


Read drug prescription

It is very important to know about what medicine is given by the doctor, for what condition, and when it needs to be taken in what dose. This information given by the doctor is called Prescription. The patients should be familiar with the medicine prescription, and the details about the medicine before purchasing it and using it. Some medications need not be prescribed by healthcare practitioners and can be purchased and used without prescription by the patients; these are called over-the-counter medications. Read the drug prescription information of Vorizol before taking it.

What is Vorizol

Vorizol is an antifungal medicine.
Vorizol is used to treat infections caused by yeast or other types of fungus.
Vorizol may also be used for purposes not listed in Vorizol guide.

Vorizol side effects

Some side effects may occur during the injection. Tell your caregiver right away if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have chest tightness or trouble breathing.
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
See also: Side effects (in more detail)
advertisement

Vorizol dosing

Usual Adult Dose for Aspergillosis -- Invasive:

Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and Scedosporium apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days and of oral therapy was 76 days (range 2 to 232 days).
-Infectious Diseases Society of America (IDSA) guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy
IDSA guidelines for empirical and preemptive therapy:
-IV: 6 mg/kg IV every 12 hours for 2 doses, then 3 mg/kg IV every 12 hours
-Oral: 200 mg orally every 12 hours

Usual Adult Dose for Candidemia:

Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and Scedosporium apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days (range 2 to 85 days) and of oral therapy was 76 days (range 2 to 232 days).
-Infectious Diseases Society of America (IDSA) guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy
IDSA guidelines for empirical and preemptive therapy:
-IV: 6 mg/kg IV every 12 hours for 2 doses, then 3 mg/kg IV every 12 hours
-Oral: 200 mg orally every 12 hours

Usual Adult Dose for Fungal Pneumonia:

Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and Scedosporium apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days and of oral therapy was 76 days (range 2 to 232 days).
-Infectious Diseases Society of America (IDSA) guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy
IDSA guidelines for empirical and preemptive therapy:
-IV: 6 mg/kg IV every 12 hours for 2 doses, then 3 mg/kg IV every 12 hours
-Oral: 200 mg orally every 12 hours

Usual Adult Dose for Pseudoallescheriosis:

Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and Scedosporium apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days (range 2 to 85 days) and of oral therapy was 76 days (range 2 to 232 days).
-Infectious Diseases Society of America (IDSA) guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy
IDSA guidelines for empirical and preemptive therapy:
-IV: 6 mg/kg IV every 12 hours for 2 doses, then 3 mg/kg IV every 12 hours
-Oral: 200 mg orally every 12 hours

Usual Adult Dose for Systemic Fungal Infection:

Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and Scedosporium apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days and of oral therapy was 76 days (range 2 to 232 days).
-Infectious Diseases Society of America (IDSA) guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy
IDSA guidelines for empirical and preemptive therapy:
-IV: 6 mg/kg IV every 12 hours for 2 doses, then 3 mg/kg IV every 12 hours
-Oral: 200 mg orally every 12 hours

Usual Adult Dose for Cutaneous Fungal Infection:

Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and Scedosporium apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days (range 2 to 85 days) and of oral therapy was 76 days (range 2 to 232 days).
-Infectious Diseases Society of America (IDSA) guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy
IDSA guidelines for empirical and preemptive therapy:
-IV: 6 mg/kg IV every 12 hours for 2 doses, then 3 mg/kg IV every 12 hours
-Oral: 200 mg orally every 12 hours

Usual Adult Dose for Fungal Infection -- Disseminated:

Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and Scedosporium apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days and of oral therapy was 76 days (range 2 to 232 days).
-Infectious Diseases Society of America (IDSA) guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy
IDSA guidelines for empirical and preemptive therapy:
-IV: 6 mg/kg IV every 12 hours for 2 doses, then 3 mg/kg IV every 12 hours
-Oral: 200 mg orally every 12 hours

Usual Adult Dose for Fungal Meningitis:

Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and Scedosporium apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days (range 2 to 85 days) and of oral therapy was 76 days (range 2 to 232 days).
-Infectious Diseases Society of America (IDSA) guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy
IDSA guidelines for empirical and preemptive therapy:
-IV: 6 mg/kg IV every 12 hours for 2 doses, then 3 mg/kg IV every 12 hours
-Oral: 200 mg orally every 12 hours

Usual Adult Dose for Fusariosis:

Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and Scedosporium apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days and of oral therapy was 76 days (range 2 to 232 days).
-Infectious Diseases Society of America (IDSA) guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy
IDSA guidelines for empirical and preemptive therapy:
-IV: 6 mg/kg IV every 12 hours for 2 doses, then 3 mg/kg IV every 12 hours
-Oral: 200 mg orally every 12 hours

Usual Adult Dose for Esophageal Candidiasis:

Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of therapy: At least 14 days and at least 7 days after symptoms resolve

Usual Adult Dose for Blastomycosis:

IDSA guidelines for CNS disease: 200 to 400 mg orally twice a day
Duration of therapy: At least 12 months and until CSF abnormalities resolve
Comments:
-An oral azole is recommended for step-down therapy after an initial regimen of liposomal amphotericin B.
-Not approved by US FDA.
Case report
Cerebral blastomycosis: 200 mg orally twice a day
Comments:
-Dose was increased to 300 mg orally twice a day after 4 weeks in an attempt to achieve a higher CNS level.
-Therapy continued for 12 months.

Usual Pediatric Dose for Aspergillosis -- Invasive:

2 to 11 years:
American Academy of Pediatrics recommendations: 9 mg/kg IV or orally every 12 hours
Maximum dose: 350 mg/dose
IDSA guidelines for invasive aspergillosis: 5 to 7 mg/kg IV every 12 hours
12 years or older:
Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and S apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days (range 2 to 85 days) and of oral therapy was 76 days (range 2 to 232 days).
-IDSA guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy

Usual Pediatric Dose for Candidemia:

2 to 11 years:
American Academy of Pediatrics recommendations: 9 mg/kg IV or orally every 12 hours
Maximum dose: 350 mg/dose
IDSA guidelines for invasive aspergillosis: 5 to 7 mg/kg IV every 12 hours
12 years or older:
Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and S apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days and of oral therapy was 76 days (range 2 to 232 days).
-IDSA guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy

Usual Pediatric Dose for Fungal Pneumonia:

2 to 11 years:
American Academy of Pediatrics recommendations: 9 mg/kg IV or orally every 12 hours
Maximum dose: 350 mg/dose
IDSA guidelines for invasive aspergillosis: 5 to 7 mg/kg IV every 12 hours
12 years or older:
Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and S apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days (range 2 to 85 days) and of oral therapy was 76 days (range 2 to 232 days).
-IDSA guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy

Usual Pediatric Dose for Pseudoallescheriosis:

2 to 11 years:
American Academy of Pediatrics recommendations: 9 mg/kg IV or orally every 12 hours
Maximum dose: 350 mg/dose
IDSA guidelines for invasive aspergillosis: 5 to 7 mg/kg IV every 12 hours
12 years or older:
Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and S apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days and of oral therapy was 76 days (range 2 to 232 days).
-IDSA guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy

Usual Pediatric Dose for Systemic Fungal Infection:

2 to 11 years:
American Academy of Pediatrics recommendations: 9 mg/kg IV or orally every 12 hours
Maximum dose: 350 mg/dose
IDSA guidelines for invasive aspergillosis: 5 to 7 mg/kg IV every 12 hours
12 years or older:
Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and S apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days (range 2 to 85 days) and of oral therapy was 76 days (range 2 to 232 days).
-IDSA guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy

Usual Pediatric Dose for Cutaneous Fungal Infection:

2 to 11 years:
American Academy of Pediatrics recommendations: 9 mg/kg IV or orally every 12 hours
Maximum dose: 350 mg/dose
IDSA guidelines for invasive aspergillosis: 5 to 7 mg/kg IV every 12 hours
12 years or older:
Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and S apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days and of oral therapy was 76 days (range 2 to 232 days).
-IDSA guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy

Usual Pediatric Dose for Fungal Infection -- Disseminated:

2 to 11 years:
American Academy of Pediatrics recommendations: 9 mg/kg IV or orally every 12 hours
Maximum dose: 350 mg/dose
IDSA guidelines for invasive aspergillosis: 5 to 7 mg/kg IV every 12 hours
12 years or older:
Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and S apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days (range 2 to 85 days) and of oral therapy was 76 days (range 2 to 232 days).
-IDSA guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy

Usual Pediatric Dose for Fungal Meningitis:

2 to 11 years:
American Academy of Pediatrics recommendations: 9 mg/kg IV or orally every 12 hours
Maximum dose: 350 mg/dose
IDSA guidelines for invasive aspergillosis: 5 to 7 mg/kg IV every 12 hours
12 years or older:
Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and S apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days and of oral therapy was 76 days (range 2 to 232 days).
-IDSA guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy

Usual Pediatric Dose for Fusariosis:

2 to 11 years:
American Academy of Pediatrics recommendations: 9 mg/kg IV or orally every 12 hours
Maximum dose: 350 mg/dose
IDSA guidelines for invasive aspergillosis: 5 to 7 mg/kg IV every 12 hours
12 years or older:
Loading Dose: 6 mg/kg IV every 12 hours for 2 doses
Maintenance Dose:
IV:
Invasive aspergillosis and serious fungal infections due to Fusarium species and S apiospermum: 4 mg/kg IV every 12 hours
Comments:
-Therapy should start with the IV loading dose on Day 1 followed by the maintenance dose.
-IV therapy should continue for at least 7 days.
-Once the patient has clinically improved and can tolerate oral medication, oral Vorizol may be used.
Candidemia in nonneutropenic patients and other deep tissue Candida infections: 3 to 4 mg/kg IV every 12 hours
Comments:
-In clinical trials, candidemia was treated using 3 mg/kg IV every 12 hours as primary therapy, while other deep tissue Candida infections were treated using 4 mg/kg IV every 12 hours as salvage therapy; appropriate dose should be based on the nature and severity of the infection.
Oral:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of Therapy:
-Invasive aspergillosis: In a clinical trial, the median duration of IV therapy was 10 days (range 2 to 85 days) and of oral therapy was 76 days (range 2 to 232 days).
-IDSA guidelines for invasive aspergillosis: At least 6 to 12 weeks; in immunosuppressed patients, throughout immunosuppression and until lesions resolve
-Candidemia in nonneutropenic patients and other deep tissue Candida infections: At least 14 days after symptoms resolve or after last positive culture, whichever is longer
Uses: Invasive aspergillosis; candidemia in nonneutropenic patients; disseminated Candida infections in skin; Candida infections in abdomen, kidney, bladder wall, wounds; serious fungal infections due to Fusarium species and S apiospermum in patients intolerant of (or refractory to) other therapy

Usual Pediatric Dose for Esophageal Candidiasis:

12 years or older:
Less than 40 kg: 100 mg orally every 12 hours
40 kg or more: 200 mg orally every 12 hours
Duration of therapy: At least 14 days and at least 7 days after symptoms resolve

Select the most affordable brand or generic drug

Generic drug is the basic drug with an active substance in it, and the name of the generic drug is same as active substance most of the times. Like Acetaminophen/Paracetemol is Generic name and it has different brand names like Tylenol, Acimol, Crocin, Calpol etc. All these Brand names contain the same Paracetemol, but the medications are manufactured by different companies, so the different brand names. Generic drug is always cheaper and affordable, and it can be replaced in place of brand name drug prescribed by the healthcare practitioner. The Generic medicine has same properties as branded medicine in terms of uses, indications, doses, side effects, so no need to worry on that. Just select the most affordable generic or branded medicine.

StrengthQuantityPrice, USDCountry
Voritrop 200mg Tablet $17.36Intas Pharmaceuticals Ltd
Voritrop 200mg Injection $25.38Intas Pharmaceuticals Ltd
VORITROP 200MG INJECTION 1 vial(s) (1 injection each) $25.38Intas Pharmaceuticals Ltd
200 mg x 1's $38.50
VORITROP 200MG TABLET 1 strip(s) (4 tablets each) $69.44Intas Pharmaceuticals Ltd
VORITROP 200MG TABLET 1 strip(s) (10 tablets each) $113.37Intas Pharmaceuticals Ltd
Vorzu 200 mg Tablet $0.01
Vorzu 200mg Injection $32.72Sun Pharmaceutical Industries Ltd
VORZU 200MG INJECTION 1 vial(s) (1 injection each) $32.72Ranbaxy Laboratories Ltd
200 mg x 1 vial x 1's $33.00
Vosicaz 200mg Injection $3.50Glenmark Pharmaceuticals Ltd
VOSICAZ 200MG INJECTION 1 vial(s) (10 ML injection each) $35.03Glenmark Pharmaceuticals Ltd
VOSICAZ 200MG TABLET 1 strip(s) (4 tablets each) $42.00Glenmark Pharmaceuticals Ltd
VOSICAZ film-coated tab 200 mg x 4's $42.00Glenmark (Critica)
Vosicaz 200mg Tablet $10.50Glenmark Pharmaceuticals Ltd
advertisement

References

  1. Dailymed."Voriconazole: dailymed provides trustworthy information about marketed drugs in the united states. dailymed is the official provider of fda label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. "Voriconazole". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  3. "Voriconazole". http://www.drugbank.ca/drugs/DB0058... (accessed August 28, 2018).

Vorizol - Frequently asked Questions

Can Vorizol be stopped immediately or do I have to stop the consumption gradually to ween off?

In some cases, it always advisable to stop the intake of some medicines gradually because of the rebound effect of the medicine.

It's wise to get in touch with your doctor as a professional advice is needed in this case regarding your health, medications and further recommendation to give you a stable health condition.

Who should not take Vorizol?

You should not take Vorizol if you are allergic to it.

Some medicines can cause unwanted or dangerous effects when used with Vorizol. Your doctor may need to change your treatment plan if you use any of the following drugs:

To make sure Vorizol is safe for you, tell your doctor if you have:

Vorizol tablets contain lactose. Before taking a Vorizol tablet, tell your doctor if you have a hereditary form of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Do not use Vorizol if you are pregnant. It could harm the unborn baby. Use effective birth control, and tell your doctor if you become pregnant during treatment.

It is not known whether Vorizol passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine.

Vorizol should not be given to a child younger than 12 years old.

How should I take Vorizol?

Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended.

Vorizol may be given to you as an injection at the start of your treatment, or until you are able to take Vorizol by mouth. Injectable Vorizol is given into a vein through an IV. You may be shown how to use an IV at home. Do not self-inject this medicine if you do not understand how to give the injection and properly dispose of used needles, IV tubing, and other items used to inject the medicine.

Injectable Vorizol is a powder medicine that must be mixed with a liquid (diluent) before using it. If you are using the injections at home, be sure you understand how to properly mix and store the medicine. Do not use the mixture if it looks cloudy or has particles in it. Call your pharmacist for new medication.

Prepare your dose only when you are ready to give an injection. If you cannot use the mixed IV medicine right away, store it in the refrigerator and use it within 24 hours. Do not freeze.

Use a disposable needle and syringe only once. Follow any state or local laws about throwing away used needles and syringes. Use a puncture-proof "sharps" disposal container (ask your pharmacist where to get one and how to throw it away). Keep this container out of the reach of children and pets.

Take Vorizol tablets or liquid at least 1 hour before or 1 hour after eating a meal.

Shake the oral suspension (liquid) well just before you measure a dose. Measure liquid medicine with the dosing syringe provided, or with a special dose-measuring spoon or medicine cup. If you do not have a dose-measuring device, ask your pharmacist for one.

Do not mix Vorizol liquid with any other medicine or liquid.

Store Vorizol tablets or liquid at room temperature away from moisture and heat. Do not store in a refrigerator or freezer. Keep the medicine bottle tightly closed when not in use. Throw away any unused liquid after 14 days.

Use this medicine for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Vorizol will not treat a viral infection such as the flu or a common cold.

Vorizol is sometimes given for up to several days after lab tests show that the infection has cleared. Very severe infections may need to be treated for several weeks.

While using Vorizol, you may need frequent blood tests. Your vision and kidney or liver function may also need to be checked.

What other drugs will affect Vorizol?

Many drugs can interact with Vorizol, and some drugs should not be used together. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide. Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Vorizol. Give a list of all your medicines to any healthcare provider who treats you.

Can Vorizol be taken or consumed while pregnant?

Please visit your doctor for a recommendation as such case requires special attention.

Can Vorizol be taken for nursing mothers or during breastfeeding?

Kindly explain your state and condition to your doctor and seek medical advice from an expert.

advertisement

Reviews

Following the study conducted by gmedication.com on Vorizol, the result is highlighted below. However, it must be clearly stated that the survey and result is based solely on the perception and impression of visitors and users of the website as well as consumers of Vorizol. We, therefore, urge readers not to base their medical judgment strictly on the result of this study but on test/diagnosis duly conducted by a certified medical practitioners or physician.

Patient reports

Patient reported useful

No survey data has been collected yet


Patient reported side effects

No survey data has been collected yet


Patient reported price estimates

No survey data has been collected yet


Patient reported frequency of use

No survey data has been collected yet


Patient reported doses

No survey data has been collected yet


Patient reported time for results

No survey data has been collected yet


Patient reported administration

No survey data has been collected yet


Patient reported age

No survey data has been collected yet


Patient reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 29 here

The information was verified by Dr. Vishal Pawar, MD Pharmacology